Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
September 02, 2020 16:01 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
September 01, 2020 08:30 ET
|
Jounce Therapeutics, Inc.
– Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead to Make $85 Million Upfront Payment and $35 Million Equity Investment – FOSTER CITY, Calif. and...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
August 07, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
June 22, 2020 09:00 ET
|
Jounce Therapeutics, Inc.
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...
Jounce Therapeutics Reports First Quarter 2020 Financial Results
May 06, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – –...